[Cryopyrin-associated periodic syndromes].

Area of Science:

• Genetics and Immunology
• Autoinflammatory Diseases
• Molecular Medicine

Background:

• Cryopyrin-associated periodic syndromes (CAPS) encompass familial cold urticaria, Muckle-Wells syndrome, and CINCA/NOMID.
• These conditions result from mutations in the NLRP3 gene, leading to dysregulated caspase-1 activity and excessive interleukin-1 production.
• While often inherited, de novo mutations are common in CINCA/NOMID.

Purpose of the Study:

• To review the genetic basis, clinical spectrum, and therapeutic outcomes of CAPS.
• To highlight the role of interleukin-1 in CAPS pathogenesis and the efficacy of targeted therapies.
• To discuss the long-term sequelae and potential for amyloidosis in untreated or inadequately treated CAPS.

Main Methods:

• Literature review of genetic mutations, clinical presentations, and treatment responses in CAPS.
• Analysis of the pathophysiology linking NLRP3 mutations to inflammatory mediator release.
• Evaluation of anti-interleukin-1 therapies (anakinra, rilonacept, canakinumab) and their impact on disease activity and complications.

Main Results:

• NLRP3 mutations trigger autoinflammatory responses, manifesting as diverse symptoms including rash, arthralgia, fever, and inflammation.
• Severe CAPS forms can lead to neurological deficits (deafness, meningitis) and skeletal abnormalities.
• Anti-interleukin-1 therapy is highly effective in achieving remission and preventing amyloidosis, though pre-existing sequelae may persist.

Conclusions:

• Targeted anti-interleukin-1 therapy represents a significant advancement in managing CAPS, offering substantial clinical improvement.
• Early diagnosis and treatment are crucial to prevent irreversible complications like neurosensory impairment and amyloidosis.
• Ongoing research into NLRP3 inflammasome modulation may offer further therapeutic avenues for these rare autoinflammatory disorders.